Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS

ClinicoEconomics and Outcomes Research - New Zealand
doi 10.2147/ceor.s169154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited